ResMed (RMD) Competitors $277.05 +3.24 (+1.18%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$275.36 -1.69 (-0.61%) As of 09/5/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RMD vs. MEDP, EHC, HIMS, BSX, SYK, MDT, BDX, IDXX, EW, and DXCMShould you be buying ResMed stock or one of its competitors? The main competitors of ResMed include Medpace (MEDP), Encompass Health (EHC), Hims & Hers Health (HIMS), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), and DexCom (DXCM). These companies are all part of the "medical" sector. ResMed vs. Its Competitors Medpace Encompass Health Hims & Hers Health Boston Scientific Stryker Medtronic Becton, Dickinson and Company IDEXX Laboratories Edwards Lifesciences DexCom Medpace (NASDAQ:MEDP) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Do insiders and institutionals have more ownership in MEDP or RMD? 78.0% of Medpace shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 20.3% of Medpace shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend MEDP or RMD? Medpace currently has a consensus target price of $412.73, suggesting a potential downside of 15.25%. ResMed has a consensus target price of $278.36, suggesting a potential upside of 0.48%. Given ResMed's stronger consensus rating and higher possible upside, analysts clearly believe ResMed is more favorable than Medpace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medpace 3 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 1.94ResMed 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 2.82 Which has higher valuation and earnings, MEDP or RMD? ResMed has higher revenue and earnings than Medpace. ResMed is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedpace$2.11B6.49$404.39M$13.4536.21ResMed$5.15B7.88$1.40B$9.5129.13 Is MEDP or RMD more profitable? ResMed has a net margin of 27.22% compared to Medpace's net margin of 18.74%. Medpace's return on equity of 67.66% beat ResMed's return on equity.Company Net Margins Return on Equity Return on Assets Medpace18.74% 67.66% 21.86% ResMed 27.22%25.62%18.69% Which has more risk and volatility, MEDP or RMD? Medpace has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Does the media refer more to MEDP or RMD? In the previous week, Medpace had 5 more articles in the media than ResMed. MarketBeat recorded 28 mentions for Medpace and 23 mentions for ResMed. ResMed's average media sentiment score of 1.36 beat Medpace's score of 0.84 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 17 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryResMed beats Medpace on 9 of the 17 factors compared between the two stocks. Get ResMed News Delivered to You Automatically Sign up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RMD vs. The Competition Export to ExcelMetricResMedMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$40.56B$10.95B$5.83B$21.36BDividend Yield0.87%1.83%6.70%3.49%P/E Ratio29.1322.1476.1529.62Price / Sales7.8830.76563.9869.38Price / Cash24.7324.5336.9925.18Price / Book6.813.5911.484.55Net Income$1.40B$212.34M$3.29B$999.70M7 Day Performance0.83%-2.29%1.27%0.58%1 Month Performance-1.00%10.37%8.56%5.67%1 Year Performance13.14%-6.65%61.18%18.25% ResMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RMDResMed4.6885 of 5 stars$277.05+1.2%$278.36+0.5%+13.1%$40.56B$5.15B29.1310,600Positive NewsAnalyst UpgradeMEDPMedpace4.3747 of 5 stars$475.51+0.5%$406.60-14.5%+45.0%$13.36B$2.11B35.355,900News CoverageAnalyst DowngradeInsider TradeEHCEncompass Health4.7392 of 5 stars$121.71-1.4%$134.00+10.1%+37.0%$12.26B$5.67B23.8240,000Positive NewsHIMSHims & Hers Health2.9033 of 5 stars$42.36-4.0%$38.92-8.1%+254.5%$9.57B$2.01B52.951,637Positive NewsBSXBoston Scientific4.4252 of 5 stars$105.56-0.2%$117.50+11.3%+31.2%$156.41B$16.75B62.8353,000Positive NewsInsider TradeSYKStryker4.9595 of 5 stars$391.48+0.5%$430.10+9.9%+9.2%$149.67B$22.60B51.8553,000Positive NewsMDTMedtronic4.8381 of 5 stars$92.72+0.8%$102.14+10.2%+3.4%$118.93B$33.54B25.5495,000Trending NewsInsider TradeBDXBecton, Dickinson and Company4.922 of 5 stars$192.84+0.8%$211.44+9.6%-17.4%$55.27B$20.18B34.6874,000Positive NewsIDXXIDEXX Laboratories4.5338 of 5 stars$647.09+0.0%$649.44+0.4%+36.1%$51.77B$3.90B53.8811,000Positive NewsShort Interest ↓EWEdwards Lifesciences4.5303 of 5 stars$81.48+0.3%$85.90+5.4%+21.1%$47.84B$5.44B11.7215,800News CoveragePositive NewsDXCMDexCom4.9393 of 5 stars$75.34+0.3%$99.89+32.6%+17.3%$29.54B$4.03B52.3210,300Positive News Related Companies and Tools Related Companies Medpace Competitors Encompass Health Competitors Hims & Hers Health Competitors Boston Scientific Competitors Stryker Competitors Medtronic Competitors Becton, Dickinson and Company Competitors IDEXX Laboratories Competitors Edwards Lifesciences Competitors DexCom Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RMD) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ResMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ResMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
